Rapid Dose Therapeutics Corp (DOSE) AI Stock Analysis

• Market Cap: C$17.80M
• Dividend Yield: N/A
• Average Volume (3M): 36.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.54
• Revenue Growth: 95.76%
• EPS Growth: 22.56%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 131,886,760
• 10 Day Avg. Volume: 35,351
• 30 Day Avg. Volume: 36,089
• PEG Ratio: -0.67
• Price to Book (P/B): -4.07
• Price to Sales (P/S): 10.16
• P/FCF Ratio: -18.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: C$0.13 ▼(-7.14% Downside)

The score is held down primarily by weak financial quality (ongoing losses, cash burn, and negative equity) and bearish technicals (below major moving averages with negative MACD). A positive partnership extension and commercialization progress provide some upside support, but valuation signals are limited due to losses and no dividend data.

Positive Factors

Revenue Growth

Positive revenue growth indicates the company's ability to expand its market reach and enhance product adoption, which is crucial for long-term sustainability and competitiveness in the biotechnology sector.

Product Innovation

The strategic partnership to develop QuickStrip® Nicotine products highlights the company's commitment to innovation and addressing global market demands, potentially increasing its market share and revenue streams.

Equity Financing

The $5 million equity financing plan aims to strengthen the company's financial position, enabling further growth and development of its innovative drug delivery solutions, which is vital for long-term operational stability.

Negative Factors

Financial Instability

The company's high leverage and negative equity indicate significant financial instability, posing risks to its ability to finance operations and invest in growth opportunities, which could hinder long-term success.

Negative Cash Flow

Negative operating cash flow suggests that the company is not generating sufficient cash from its core operations, which could limit its ability to invest in growth and manage financial obligations effectively over time.

Profitability Challenges

Persistent negative margins highlight significant profitability challenges, indicating that the company struggles to cover costs and generate profits, which may impact its long-term viability and competitiveness.

Rapid Dose Therapeutics Corp Business Overview & Revenue Model

Company Description

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.

How the Company Makes Money

Rapid Dose Therapeutics Corp generates revenue primarily through the sale and licensing of its QuickStrip™ technology. The company partners with pharmaceutical, nutraceutical, and cannabis companies to incorporate QuickStrip™ into their product lines, earning income from manufacturing agreements and royalties. Additionally, Rapid Dose may engage in joint ventures or strategic collaborations to expand its application range and market penetration, further boosting its revenue streams.

Rapid Dose Therapeutics Corp Financial Statement Overview

Summary

Rapid Dose Therapeutics Corp exhibits significant financial challenges with negative profitability, high leverage, and cash flow issues. Despite some revenue growth, the company's financial stability is compromised by consistent losses and a weak balance sheet. Urgent improvements in cost management and capital structure are necessary to stabilize financial health.

Income Statement

The company is struggling with profitability as evidenced by negative margins across the board. The TTM gross profit margin is -17.02%, highlighting the challenge in covering the cost of goods sold. Net profit margin is severely negative, indicating significant losses. Revenue growth rate is positive, showcasing some capability to increase sales, but this is overshadowed by persistent negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a highly leveraged position with a negative stockholders' equity, resulting in an undefined debt-to-equity ratio, which signals financial instability. The company has negative equity ratio and significant liabilities, posing a risk to financial stability and growth. Return on equity is not calculable due to negative equity, further indicating financial distress.

Cash Flow

Operating cash flow is negative, which is concerning as it reflects cash outflows from core operations. Free cash flow is also negative, indicating a lack of cash generated after capital expenses. The free cash flow growth rate is undefined due to negative values, and the ratios to net income are skewed by negative figures, highlighting liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2022	Dec 2020
Income Statement
Total Revenue	2.63M	2.09M	1.02M	1.75M	718.30K	755.20K
Gross Profit	1.36M	1.18M	563.41K	1.34M	372.40K	699.85K
EBITDA	-3.03M	-3.93M	-3.02M	-7.59M	-2.92M	-987.00K
Net Income	-4.59M	-5.40M	-4.31M	-8.49M	-3.81M	-1.80M
Balance Sheet
Total Assets	4.25M	1.63M	1.89M	3.07M	2.25M	3.83M
Cash, Cash Equivalents and Short-Term Investments	8.57K	20.72K	161.06K	34.44K	27.59K	70.26K
Total Debt	5.67M	2.61M	2.45M	1.43M	1.61M	2.06M
Total Liabilities	10.13M	6.84M	5.04M	2.82M	4.92M	5.41M
Stockholders Equity	-5.88M	-5.21M	-3.16M	251.56K	-2.67M	-1.58M
Cash Flow
Free Cash Flow	-965.32K	-1.15M	-2.29M	-3.04M	-863.92K	-1.63M
Operating Cash Flow	-958.68K	-1.15M	-2.29M	-3.00M	-863.92K	-1.62M
Investing Cash Flow	2.54M	-5.74K	0.00	1.85M	0.00	-9.12K
Financing Cash Flow	968.20K	1.01M	2.43M	1.13M	856.53K	1.65M

Rapid Dose Therapeutics Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.15, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.90 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOSE.

Rapid Dose Therapeutics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	47 Neutral	C$12.98M	-1.60	―	―	-3.93%	-575.24%
DOSE	43 Neutral	C$17.80M	-3.78	―	―	95.76%	22.56%
BCT	43 Neutral	C$18.90M	-0.15	-409.25%	―	―	62.01%
HEM	41 Neutral	C$16.96M	-3.09	―	―	―	-24.89%

Rapid Dose Therapeutics Corp Corporate Events

Rapid Dose Therapeutics Pays Convertible Note Interest in Shares

Rapid Dose Therapeutics Corp. will issue 362,708 common shares to holders of its secured convertible notes to satisfy approximately $47,154 in quarterly interest accrued as of December 31, 2025, with issuance expected by January 15, 2026. The interest payment in shares stems from an amended and restated note financing originally completed in 2023, under which the company extended the maturity of $3.08 million in promissory notes and associated warrants to November 30, 2026; the notes carry an 18% annual interest rate payable in stock at the Canadian Securities Exchange quarter-end closing price, a structure that preserves cash but dilutes existing shareholders while providing continued support from noteholders.

The most recent analyst rating on (TSE:DOSE) stock is a Hold with a C$0.13 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.

Rapid Dose Therapeutics Extends Convertible Notes Maturity Date

Rapid Dose Therapeutics Corp. announced an extension of the maturity date for its secured convertible notes, originally set to mature on November 30, 2025, to November 30, 2026. This extension involves noteholders agreeing to new terms, including an increased interest rate from 12% to 18% per annum and an extension fee payable in common shares. The company also plans to issue common shares to satisfy accrued interest, with securities subject to a hold period. This move is part of a related party transaction involving company insiders and is exempt from certain regulatory requirements.

Rapid Dose Therapeutics Extends Nicotine Partnership and Advances NicStrip™ Commercialization

Rapid Dose Therapeutics Corp. has announced a seven-month extension of its collaboration with an international nicotine partner, valued at up to $1.8 million CAD. This extension supports further evaluation and potential commercialization of NicStrip™, an oral thin film nicotine product. The company has made significant strides in its nicotine portfolio, including a Health Canada submission, ongoing clinical evaluations, and expanded patent protection. These efforts align with global trends towards non-combustible nicotine alternatives, positioning RDT to capitalize on a growing market focused on harm reduction and smoke-free products.